Ivana Magovčević-Liebisch, Vigil

Vig­il rais­es $90M in neu­ro­science 're­nais­sance.' Is an IPO around the cor­ner?

A cou­ple of years ago, Am­gen joined Big Phar­ma’s mass ex­o­dus from neu­ro­science, as ex­ecs ei­ther aban­doned or trimmed back their pro­grams in the field.

Now, a small Cam­bridge, MA-based biotech is sprint­ing to­ward the clin­ic with two of Am­gen’s old TREM2 as­sets, and in­vestors are putting down $90 mil­lion ahead of what they be­lieve could be neu­ro­science’s big come­back.

Vig­il Neu­ro­science un­veiled a meaty Se­ries B round led by Arie Bellde­grun’s Vi­da Ven­tures on Wednes­day morn­ing, bring­ing the biotech’s to­tal raise to $140 mil­lion. The com­pa­ny launched less than a year ago with a $50 mil­lion Se­ries A round — and CEO Ivana Magov­če­vić-Liebisch says their next fi­nanc­ing will like­ly take place on the pub­lic mar­kets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA